- MK-2206 2HCl
-
- $30.00 / 1kg
-
2023-09-07
- CAS:1032350-13-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000t/year
- MK-2206 2HCl
-
- $0.00 / 25KG
-
2023-01-31
- CAS:1032350-13-2
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- MK-2206 2HCl
-
- $2.00 / 1kg
-
2019-07-06
- CAS:1032350-13-2
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | MK-2206 2HCl Basic information |
| Product Name: | MK-2206 2HCl | | Synonyms: | MK-2206 Dihydrochloride;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride;8-[4-(1-AMinocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one Hydrochloride;8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride MK-2206;MK-2206 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one dihydrochloride;MK 2206 (hydrochloride);MK-2206 dihydrochloride, >=98% | | CAS: | 1032350-13-2 | | MF: | C25H22ClN5O | | MW: | 443.94 | | EINECS: | | | Product Categories: | Inhibitor;PI3K/Akt/mTOR;Inhibitors;Akt;mTOR;PI3K;Amines;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 1032350-13-2.mol |  |
| | MK-2206 2HCl Chemical Properties |
| Melting point | >255°C (dec.) | | storage temp. | -20°C | | solubility | Soluble in DMSO (up to 10 mg/ml with warming) | | form | Yellow powder. | | color | Yellow | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| | MK-2206 2HCl Usage And Synthesis |
| Description | MK-2206 (CAS 1032350-13-2) is a potent and selective allosteric inhibitor of Akt (IC50’s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the?in vitro?and?in vivo?antitumor efficacy of several standard chemotherapeutic agents.1?It was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle.2?MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis.3 | | Uses | AZD 6244 and MK 2206 are targeted small-molecule drugs that inhibit MEK and AKT responses. The combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vivo and leads to increased survival rates in mice bearing highly aggressive human lung tumors. Antitumor agents. Potent AKT inhibitor. | | Uses | A highly selective inhibitor of Akt. Akt1, IC50=8 nM; Akt2, IC50=12 nM; Akt3, IC50=65 nM. | | Uses | AZD 6244 and MK 2206 are targeted small-molecule drugs that inhibit MEK and AKT responses. The combination of AZD6244 and MK2206 has a significant synergistic effect on tumor growth in vitro and in vi
vo and leads to increased survival rates in mice bearing highly aggressive human lung tumors. Antitumor agents. | | target | Akt1 | | storage | -20°C | | References | 1) Hirai?et al.?(2010),?MK-2206, an Allosteric Akt inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular targeted Drugs In vitro and In vivo; Mol. Cancer Ther.?9?1956
2) Lai?et al.?(2012),?A novel PKB/Akt inhibitor, MK-2206, effectively inhibits insulin-stimulated glucose metabolism and protein synthesis in isolated rat skeletal muscle; Biochem. J.?447?137
3) Jiao?et al.?(2013),?MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death; Mol. Cell Biochem.?382?217 |
| | MK-2206 2HCl Preparation Products And Raw materials |
|